21st Century treatment of diabetic retinopathy

References

• Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int. J. Clin. Pract.60(11), 1471–1483 (2006).
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris FL, Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology110(9), 1677–1682 (2003).
   PubMed Web of Science ®Google Scholar
• Jain A, Sarraf D, Fong D. Preventing diabetic retinopathy through control of systemic factors. Curr. Opin. Ophthalmol.14(6), 389–394 (2003).
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H. Pathogenesis of diabetic retinopathy and the renin–angiotensin system. Ophthalmic Physiol. Opt.23(6), 495–501 (2003).
   PubMed Web of Science ®Google Scholar
• Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risk of progression of retinopathy and visual loss related to tight control of blood pressure in Type 2 diabetes mellitus. UKPDS 69. Arch. Ophthalmol.122(11), 1631–1640 (2004).
   PubMed Web of Science ®Google Scholar
• Sheth HG, Aslam S, Davies N. Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. Br. Med. J.332(7552), 1272–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Sjolie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res. Clin. Pract.76(Suppl. 1), S31–S39 (2007).
   PubMed Web of Science ®Google Scholar
• Lang GE. Laser treatment of diabetic retinopathy. Dev. Ophthalmol.39, 48–68 (2007).
   PubMedGoogle Scholar
• Yi Q, Bamroongsuk P, McCarty DJ, Mukesh BN, Harper CA. Clinical outcomes following laser photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital. Clin. Experiment. Ophthalmol.31(4), 305–309 (2003).
   PubMed Web of Science ®Google Scholar
• Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologia221(2), 95–102 (2007).
   Google Scholar
• Lewis H. Role of vitrectomy in the treatment of diabetic macular edema. Am. J. Ophthalmol.131(1), 123–125 (2001).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase® for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injectin of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am. J. Ophthalmol.140(4), 573–584 (2005).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase® for Vitreous Hemorrhage Study Groups. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am. J. Ophthalmol140(4), 585–597 (2005).
   PubMed Web of Science ®Google Scholar
• Trese MT. Enzymatic-assisted vitrectomy. Eye16(4), 365–368 (2002).
   PubMed Web of Science ®Google Scholar
• Sakuma T, Tanaka M, Mizota A et al. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest. Ophthalmol. Vis. Sci.46(9), 3295–3299 (2005).
   PubMed Web of Science ®Google Scholar
• Setter SM, Campbell RK, Cahoon CJ. Biochemical pathways for microvascular complications of diabetes mellitus. Ann. Pharmacother.37(12), 1858–1866 (2003).
   PubMed Web of Science ®Google Scholar
• Frank RN. Diabetic retinopathy. N. Engl. J. Med.350(1), 48–58 (2004).
   PubMed Web of Science ®Google Scholar
• Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr. Drug Targets6(4), 475–86 (2005).
   PubMed Web of Science ®Google Scholar
• Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes55(10), 2757–2762 (2006).
   PubMed Web of Science ®Google Scholar
• Lang GE. Treatment of diabetic retinopathy with protein kinase C subtype Β inhibitor. Dev. Ophthalmol.39, 157–165 (2007).
   PubMedGoogle Scholar
• Idris I, Donnelly R. Protein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab. Vasc. Dis. Res.3(3), 172–178 (2006).
   PubMedGoogle Scholar
• The PKC–DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes54(7), 2188–2197 (2005).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Davis MD, Girach A et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
   PubMed Web of Science ®Google Scholar
• Pomero F, Allione A, Beltramo E et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia46(3), 416–419 (2003).
   PubMed Web of Science ®Google Scholar
• Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med.9(3), 294–299 (2003).
   PubMed Web of Science ®Google Scholar
• Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes54(5), 1559–1565 (2005).
   PubMed Web of Science ®Google Scholar
• Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr. Diabetes Rev.3(1), 3–14 (2007).
   PubMedGoogle Scholar
• Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J.18(12), 1450–1452 (2004).
   PubMed Web of Science ®Google Scholar
• Adamis AP. Is diabetic retinopathy an inflammatory disease? Br. J. Ophthalmol.86(4), 363–365 (2002).
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Mitsiades N et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-suppression. FASEB J.16(3), 438–440 (2002).
   PubMed Web of Science ®Google Scholar
• Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes56(2), 337–345 (2007).
   PubMed Web of Science ®Google Scholar
• Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol. Metab. Clin. North Am.31(3), 779–793 (2002).
   PubMed Web of Science ®Google Scholar
• Kohner EM. Aspirin for diabetic retinopathy. Br. Med. J.327(7423), 1060–1061 (2003).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology113(9), 1533–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohamed S et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol.91(2), 199–203 (2007).
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev. Ophthalmol.39, 96–110 (2007).
   PubMedGoogle Scholar
• Pearson P, Levy B; Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. Program and abstracts of the Association for Research in Vision and Ophthalmology 2005 Annual Meeting, FL, USA (2005) (Abstract 4673).
   Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol.125(3), 309–317 (2007).
   PubMed Web of Science ®Google Scholar
• Jaffe GJ. Update on pharmacologic treatment of diabetic macular edema. Retina Today2, 49–54 (2006).
   Google Scholar
• Clermont A, Bursell SE, Feener EP. Role of the angiotensin II Type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. Suppl.24(1), S73–S80 (2006).
   Google Scholar
• Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol.38(5–6), 752–765 (2006).
   PubMed Web of Science ®Google Scholar
• Sjolie AK, Porta M, Parving HH, Bilous R, Klein R. The DIRECT Programme Study Group. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J. Renin Angiotensin Aldosterone Syst.6(1), 25–32 (2005).
   PubMed Web of Science ®Google Scholar
• Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am.19(3), 335–344 (2006).
   PubMedGoogle Scholar
• Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol.90, 1542–1547 (2006).
   PubMed Web of Science ®Google Scholar
• Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug Targets6(4), 511–5124 (2005).
   PubMed Web of Science ®Google Scholar
• Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci.1082, 151–171 (2006).
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel MJ et al.; Macugen Diabetic Retinopathy Study Group. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology112(10), 1747–1757 (2005).
   PubMed Web of Science ®Google Scholar
• Adamis AP, Altaweel M, Bressler NM et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology113(1), 23–28 (2006).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology113(10), 1695–1705 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging36(4), 331–335 (2005).
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology113(3), 363–372 (2006).
   PubMed Web of Science ®Google Scholar
• Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology113(10), 1706–1712 (2006).
   PubMed Web of Science ®Google Scholar
• Sherris D. Ocular drug development – future directions. Angiogenesis10(2), 71–76 (2007).
   Google Scholar
• Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina24(5), 676–698 (2004).
   PubMed Web of Science ®Google Scholar
• Kupperman BD. Transcleral uptake and diffusion of bevacizumab (Avastin) and ranibizumab (Lucentis). Retina Today2, 27–31 (2007).
   Google Scholar
• Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem.13(27), 3307–3317 (2006).
   PubMed Web of Science ®Google Scholar
• Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin. Investig. Drugs16(1), 73–82 (2007).
   PubMed Web of Science ®Google Scholar
• Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev. Ophthalmol.39, 111–121 (2007).
   PubMedGoogle Scholar
• Gao BB, Clermont A, Rook S et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med.13(2), 181–188 (2007).
   PubMed Web of Science ®Google Scholar
• Fletcher EL, Phipps JA, Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. Clin. Exp. Optom.88(3), 132–145 (2005).
   PubMedGoogle Scholar
• Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br. J. Ophthalmol.89(1), 74–80 (2005).
   PubMed Web of Science ®Google Scholar